share_log

Avalo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Doyle Mittie

Avalo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Doyle Mittie

Avalo Therapeutics | 4:持股变动声明-高管 Doyle Mittie
美股sec公告 ·  07/16 16:27
Moomoo AI 已提取核心信息
Chief Medical Officer of Avalo Therapeutics, Doyle Mittie, engaged in a transaction involving the company's stock on July 15, 2024. The specific details of the transaction, including the number of shares, nature of shares, transaction price, and total value, were not disclosed in the announcement. Following the action, the updated number of shares held by Doyle Mittie in Avalo Therapeutics remains undisclosed.
Chief Medical Officer of Avalo Therapeutics, Doyle Mittie, engaged in a transaction involving the company's stock on July 15, 2024. The specific details of the transaction, including the number of shares, nature of shares, transaction price, and total value, were not disclosed in the announcement. Following the action, the updated number of shares held by Doyle Mittie in Avalo Therapeutics remains undisclosed.
2024年7月15日,Avalo Therapeutics的首席医疗官Doyle Mittie进行了一笔涉及该公司股票的交易。交易的具体细节,包括股份数量、股票性质、成交价格和总价值,在公告中未披露。在此次交易后,Doyle Mittie在Avalo Therapeutics持有的股份数量未公开。
2024年7月15日,Avalo Therapeutics的首席医疗官Doyle Mittie进行了一笔涉及该公司股票的交易。交易的具体细节,包括股份数量、股票性质、成交价格和总价值,在公告中未披露。在此次交易后,Doyle Mittie在Avalo Therapeutics持有的股份数量未公开。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息